Cyclooxygenase-2 polymorphisms and susceptibility to gastric carcinoma: A meta-analysis

Table 1 Characteristics and quality assessment of 10 included case-control studies

Study	Yr	Country	Ethnicity	Polymorphisms of COX-2	No. of participants	Quality scores
Pereira et al[25]	2006	Portugal	Caucasians	-765G>C	73a/210c	33
Liu et al[27]	2006	China	Asians	-765G>C, -1195G>A, Gly587Arg(G>A)	248a/427c	33
Zhang et al[28]	2006	China	Asians	-765G>C, -1195G>A, -1290A>G	323a/646c	28
Jiang et al[29]	2007	China	Asians	-1195G>A, 8473T>C	254a/304c	36
Hou et al[26]	2007	Poland	Caucasians	-765G>C, IVS5-275T>G, IVS7+111T>C, V102V(G>C), *429T>C, *2430C>T	464a/480c	33
Canzian et al[32]	2008	Venezuela	Hispanics	IVS5-275T>G, V102V, *429T>C	1169a/1863b	39
Zhu et al[30]	2008	China	Asians	-765G>C, 587codonG>A	140a/125c	37
Saxena et al[33]	2008	India	Indians	-765G>C	62a/241d	34
Sitarz et al[18]	2008	Netherlands	Dutch	-765G>C	241a/100c	31
Tang et al[31]	2009	China	Asians	-765G>C	100a/105c	29

^aGastric cancer;

^bPrecancerous gastric lesions;

^cHealthy controls;

^dBenign gastric diseases. COX-2: Cyclooxygenases-2.

Table 2 The genotype distribution of COX-2 polymorphisms and the variant allele frequency n (%)

Polymorphism	Study	Cases		Controls		Variant allele frequency	OR (95% CI)
		n	Variant allele carriers	n	Variant allele carriers
-765G>C	Pereira et al[25]	73	37 (51)	210	80 (38)	0.22	1.67 (0.98-2.86)
	Liu et al[27]	388	42 (11)	427	43 (10)	0.05	1.08 (0.69-1.70)
	Zhang et al[28]	323	35 (11)	646	26 (4)	0.02	2.90 (1.71-4.91)
	Hou et al[26]	290	80 (28)	409	121 (30)	0.16	0.91 (0.65-1.27)
	Zhu et al[30]	140	38 (27)	125	20 (26)	0.06	1.96 (1.07-3.59)
	Saxena et al[33]	62	48 (77)	241	70 (29)	0.16	8.38 (4.34-16.16)
	Sitarz et al[18]	241	65 (27)	100	41 (41)	0.25	0.53 (0.33-0.87)
	Tang et al[31]	100	45 (45)	105	29 (28)	0.06	2.14 (1.20-3.84)
						Pooled OR = 1.71 (1.01-2.90)
-1195G/A	Liu et al[27]	389	316 (81)	427	322 (75)	0.50	1.41 (1.01-1.98)
	Zhang et al[28]	323	291 (90)	646	510 (79)	0.52	2.43 (1.61-3.66)
	Jiang et al[29]	254	206 (81)	304	242 (80)	0.26	1.17 (0.77-1.77)
						Pooled OR = 1.58 (1.05-2.38)
Gly587Arg (G>A)	Liu et al[27]	386	18 (15)	407	23 (6)	0.03	0.82 (0.43-1.54)
-1290A>G	Zhang et al[28]	323	40 (12)	646	54 (8)	0.04	1.55 (1.01-2.39)
8473T/C	Jiang et al[29]	254	95 (37)	304	105 (34)	0.11	1.13 (0.80-1.60)
IVS5-275T>G	Hou et al[26]	311	93 (30)	421	123 (29)	0.16	1.03 (0.75-1.42)
	Canzian et al[32]	108	36 (33)	1003	392 (39)	0.22	0.78 (0.51-1.19)
						Pooled OR = 0.93 (0.71-1.21)
IVS7+111T>C	Hou et al[26]	299	78 (26)	421	114 (27)	0.15	0.95 (0.68-1.33)
V102V	Hou et al[26]	302	72 (24)	410	125 (30)	0.16	0.71 (0.51-1.00)
	Canzian et al[32]	115	32 (28)	1053	214 (20)	0.11	1.51 (0.98-2.3)
						Pooled OR = 1.03 (0.49-2.14)
*429T>C	Hou et al[26]	304	167 (55)	165 (40)	251 (60)	0.36	0.80 (0.59-1.08)
	Canzian et al[32]	53 (49)	56 (51)	398 (38)	644 (62)	0.38	0.65 (0.44-0.97)
						Pooled OR = 0.74 (0.59-0.95)
*2430C >T	Hou et al[26]	289 (94)	19 (6)	399 (98)	10 (2)	0.01	2.62 (1.20-5.73)
587codonG>A	Zhu et al[30]	121 (86)	19 (14)	112 (90)	13 (10)	0.06	1.35 (0.64-2.87)

n: No. of patients; OR: odds ratio; 95% CI: 95% confidence interval; COX-2: Cyclooxygenases-2.